Alnylam Pharmaceuticals this week released additional data from an ongoing phase I study of its liver cancer drug ALN-VSP in conjunction with the presentation of the findings at this year's American Society of Clinical Oncology annual meeting.

"The initial data with ALN-VSP are encouraging and we look forward to continued dose escalation to explore tolerability and potential for tumor response," Josep Tabernero, who is heading up the study at Vall d'Hebron University Hospital in Barcelona, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.